NCT06887023

Brief Summary

The main aim of this observational study is to understand the clinicopathological and prognostic information of IPNB, a rare tumor. The participants have already received treatment during their previous routine medical management and took part in follow - up. We will look into their survival information after previous medical visits and treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
118

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2025

Completed
17 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2025

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

March 14, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 20, 2025

Completed
Last Updated

March 20, 2025

Status Verified

February 1, 2025

Enrollment Period

2 months

First QC Date

March 14, 2025

Last Update Submit

March 14, 2025

Conditions

Bile Duct Neoplasms Malignant

Keywords

intraductal papilloma of bile ductmalignancyprogressionrisk factorsprognosis

Outcome Measures

Primary Outcomes (1)

  • death

    Died of various causes after treatment

    From January 2014 to June 2024

Eligibility Criteria

Sexall(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with IPNB from eight Chinese hospitals over a 10-year period

You may qualify if:

  • IPNB with or without malignant transformation was confirmed by pathological examination

You may not qualify if:

  • missing other essential clinical data
  • coexisting malignant tumors of other digestive system organs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

the First Hospital of Jilin University

Changchun, Jililn, 130000, China

Location

MeSH Terms

Conditions

NeoplasmsDisease Progression

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

March 14, 2025

First Posted

March 20, 2025

Study Start

December 1, 2024

Primary Completion

January 15, 2025

Study Completion

February 1, 2025

Last Updated

March 20, 2025

Record last verified: 2025-02

Locations

CN(1)